Pharmacokinetics and bioavailability of furosemide in sheep

被引:4
|
作者
Corum, Duygu Durna [1 ]
Corum, Orhan [1 ]
Atik, Orkun [2 ]
Cetin, Gul [3 ]
Zhunushova, Aidai [4 ,5 ]
Uney, Kamil [5 ]
机构
[1] Univ Kastamonu, Fac Vet Med, Dept Pharmacol & Toxicol, Kastamonu, Turkey
[2] Afyon Kocatepe Univ, Fac Vet Med, Dept Pharmacol & Toxicol, Afyon, Turkey
[3] Univ Erzincan Binali Yildirim, Fac Pharm, Dept Pharmacol, Erzincan, Turkey
[4] Kyrgyz Turkish Manas Univ, Fac Vet Med, Bishkek, Kyrgyzstan
[5] Selcuk Univ, Fac Vet Med, Dept Pharmacol & Toxicol, Konya, Turkey
关键词
bioavailability; furosemide; pharmacokinetics; sheep; PLASMA; PHARMACODYNAMICS; DIURETICS; EXERCISE; RENIN;
D O I
10.1111/jvp.12937
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and bioavailability of furosemide were determined following intravenous (IV), intramuscular (IM), and subcutaneous (SC) administrations at 2.5 mg/kg dose in sheep. The study was conducted on six healthy sheep in a three-way, three-period, crossover pharmacokinetic design with a 15-day washout period. In first period, furosemide was randomly administered via IV to 2 sheep, IM to 2 sheep and SC to 2 sheep. In second and third periods, each sheep received furosemide via different routes of administration with the 15-day washout period. Plasma concentrations were determined using a high-performance liquid chromatography assay and analyzed by noncompartmental method. The mean total clearance and volume of distribution at steady state following IV administration were 0.24 L h(-1) kg(-1) and 0.17 L/kg, respectively. The elimination half-life was similar for all administration routes. The mean peak plasma concentrations of IM and SC administration were 10.33 and 3.18 mu g/ml at 0.33 and 0.42 hr, respectively. The mean bioavailability of IM and SC administration was 97.91% and 37.98%, respectively. The IM injection of furosemide may be the alternative routes in addition to IV. However, further research is required to determine the effect of dose and route of administration on the clinical efficacy of furosemide in sheep.
引用
收藏
页码:657 / 662
页数:6
相关论文
共 50 条
  • [21] PHENYTOIN - PHARMACOKINETICS AND BIOAVAILABILITY
    GUGLER, R
    MANION, CV
    AZARNOFF, DL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1976, 19 (02) : 135 - 142
  • [22] BIOAVAILABILITY AND PHARMACOKINETICS OF FEMOXETINE
    MENGEL, H
    LUND, J
    LANGE, J
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1983, 33-1 (03): : 462 - 466
  • [23] METHOTREXATE - BIOAVAILABILITY AND PHARMACOKINETICS
    CAMPBELL, MA
    PERRIER, DG
    DORR, RT
    ALBERTS, DS
    FINLEY, PR
    CANCER TREATMENT REPORTS, 1985, 69 (7-8): : 833 - 838
  • [24] CHLORPROPAMIDE BIOAVAILABILITY AND PHARMACOKINETICS
    HUUPPONEN, R
    LAMMINTAUSTA, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1981, 19 (07) : 331 - 333
  • [25] BIOAVAILABILITY AND PHARMACOKINETICS OF OXAZEPAM
    SONNE, J
    LOFT, S
    DOSSING, M
    VOLLMERLARSEN, A
    OLESEN, KL
    VICTOR, M
    ANDREASEN, F
    ANDREASEN, PB
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (04) : 385 - 389
  • [26] DISOPYRAMIDE PHARMACOKINETICS AND BIOAVAILABILITY
    DUBETZ, DK
    BROWN, NN
    HOOPER, WD
    EADIE, MJ
    TYRER, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 6 (03) : 279 - 281
  • [27] Polymeric microcontainers improve oral bioavailability of furosemide
    Nielsen, Line Hagner
    Melero, Ana
    Keller, Stephan Sylvest
    Jacobsen, Jette
    Garrigues, Teresa
    Rades, Thomas
    Mullertz, Anette
    Boisen, Anja
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 504 (1-2) : 98 - 109
  • [28] PHARMACOKINETICS AND BIOAVAILABILITY OF ALIZAPRIDE
    HOUIN, G
    BREE, F
    TILLEMENT, JP
    SEMAINE DES HOPITAUX, 1982, 58 (06): : 339 - 344
  • [29] PHARMACOKINETICS AND BIOAVAILABILITY OF PAPAVERINE
    JUHRAN, W
    HAASE, W
    GOTZ, R
    FLEISSIG, W
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1975, 25 (05): : 771 - 773
  • [30] DISOPYRAMIDE PHARMACOKINETICS AND BIOAVAILABILITY
    DUBETZ, DK
    BROWN, NN
    HOOPER, WD
    EADIE, MJ
    TYRER, JH
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1978, 5 (03) : 269 - 269